01:10 , Oct 22, 2018 |  BC Extra  |  Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. This...
23:32 , Oct 19, 2018 |  BC Extra  |  Company News

FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said Friday that FDA and EMA have both pushed back their reviews of anti-PD-1 mAb Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab for first-line non-small cell lung cancer. The company also...
18:38 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL) Mouse studies suggest hematopoietic stem cells (HSCs) expressing IFNα could help treat B cell ALL (B-ALL). In a mouse model of B-ALL, HSCs modified to express IFNα decreased leukemic cell...
18:16 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Alphamab's bispecific checkpoint antibody enters clinic in Australia, Chinese trials planned

Alphamab Oncology (Suzhou, China) started an Australian Phase I trial of KN046 to treat advanced solid tumors. Data are expected this quarter. Alphamab also said China's National Medical Products Administration (NMPA) approved an IND for...
23:03 , Oct 2, 2018 |  BC Extra  |  Politics & Policy

Nobel Prize goes to discoverers of checkpoint targets

Discoveries that led to a pair of first-in-world approvals for two blockbuster cancer drugs from Bristol-Myers Squibb Co. (NYSE:BMY) and touched off a new era in treating cancer were the focus of this year's Nobel...
21:15 , Sep 28, 2018 |  BioCentury  |  Finance

Activating Akrevia

Akrevia Therapeutics LLC parlayed preclinical proof-of-concept data from its tumor-activated therapies into a $30 million series A round co-led by Atlas Venture and F-Prime Capital Partners. Akrevia, which emerged from stealth on Sept. 27, uses...
17:56 , Sep 28, 2018 |  BC Week In Review  |  Financial News

F-Prime, Atlas lead Akrevia's $30M series A

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched on Sept. 27 with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture. Akrevia’s Aklusion platform enables biological molecules such as antibodies,...
00:07 , Sep 28, 2018 |  BC Innovations  |  Tools & Techniques

Deconstructing tox in immuno-oncology

The best route to improving preclinical toxicity in immunotherapies could lie in reverse translation, feeding clinical data back into the preclinical space to inform model development, rather than trying to guess...
15:37 , Sep 27, 2018 |  BC Extra  |  Financial News

F-Prime, Atlas lead Akrevia's $30M series A

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture. Akrevia’s Aklusion platform enables biological molecules such as antibodies, cytokines and chemokines...
17:39 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer; lung cancer Mouse studies suggest combining reactive nitrogen species neutralizers with inhibitors of CTLA-4, PD-1 and other immune checkpoints could help treat castration-resistant prostate cancer (CRPC) and lung cancer. In a mouse...